Revenue and entity-wide disclosures - Narrative (Details) SFr in Thousands, $ in Millions |
12 Months Ended | 40 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2025
CHF (SFr)
|
Dec. 31, 2024
CHF (SFr)
|
Dec. 31, 2023
CHF (SFr)
|
Dec. 31, 2022
CHF (SFr)
|
Mar. 31, 2025
CHF (SFr)
|
Mar. 31, 2025
USD ($)
|
|
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Research and development expense | SFr 40,194 | SFr 48,604 | SFr 48,784 | |||
| Total Revenues | 0 | 4,970 | 7,038 | |||
| Co-development Agreement with Orano Med | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Research and development expense reimbursement | SFr 2,300 | |||||
| Research and development expense | 600 | |||||
| Licence and Collaboration Agreement with Novartis | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Total Revenues | SFr 5,000 | SFr 7,000 | SFr 18,600 | $ 20.0 | ||
| Novartis Option and Equity Rights Agreement | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Total Revenues | SFr 150,000 | |||||